Skip to content

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18: a Mixed-methods Assessment of Acceptance of HPV Vaccine With Experiments on Communication Strategies

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06347627
Enrollment
1324
Registered
2024-04-04
Start date
2023-12-22
Completion date
2024-01-22
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

HPV Vaccine

Brief summary

This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.

Detailed description

This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on 'components of message.' The sixteen experimental messages will be developed based on real social media messages posted between November 2021 and April 2022, when the Japanese government prepared to reinstate an active recommendation of HPV vaccines for eligible girls after eight and a half years of suspension. The sixteen messages will assess four factors: messenger, style, content, and misinformation. Each message will be similar except for one variable in consideration. The messenger component will be whether the message is from an individual or an organization. As individual messengers, the study will set a fictional male or female with common Japanese names who actively communicate about HPV vaccines. As organizational messengers, the study will use the existing accounts of the Ministry of Health, Labour and Welfare or the Japan Cancer Society or a fictional account of an anti-vaccine group. The style component will be whether the message conveys information through storytelling or scientific data. Messages will include personal stories for the storytelling style and statistics for the scientific data style. The content component will be whether the message conveys information about the effectiveness of the HPV vaccine in preventing diseases or the safety of the HPV vaccine. The contents will be built on both factual information and misconceptions about HPV vaccine safety and effectiveness that are often mentioned in the actual social media posts. The misinformation component will be whether the message conveys misinformation or factual information. The study will debrief all respondents exposed to misinformation after the survey. Lastly, the study will collect data as a post-experiment survey to evaluate how an online message influenced caregivers' trust, confidence, and motivation to vaccinate.

Interventions

BEHAVIORALGroup 1 (I x S x S x F)

Experimental message: Individual x Safety x Storytelling x Factual

BEHAVIORALGroup 2 (O x S x S x F)

Experimental message: Organization x Safety x Storytelling x Factual

BEHAVIORALGroup 3 (I x E x S x F)

Experimental message: Individual x Effectiveness x Storytelling x Factual

BEHAVIORALGroup 4 (O x E x S x F)

Experimental message: Organization x Effectiveness x Storytelling x Factual

BEHAVIORALGroup 5 (I x S x S x M)

Experimental message: Individual x Safety x Storytelling x Misinformation

BEHAVIORALGroup 6 (O x S x S x M)

Experimental message: Organization x Safety x Storytelling x Misinformation

BEHAVIORALGroup 7 (I x E x S x M)

Experimental message: Individual x Effectiveness x Storytelling x Misinformation

BEHAVIORALGroup 8 (O x E x S x M)

Experimental message: Organization x Effectiveness x Storytelling x Misinformation

BEHAVIORALGroup 9 (I x S x D x F)

Experimental message: Individual x Safety x Scientific data x Factual

BEHAVIORALGroup 10 (O x S x D x F)

Experimental message: Organization x Safety x Scientific data x Factual

BEHAVIORALGroup 11 (I x E x D x F)

Experimental message: Individual x Effectiveness x Scientific data x Factual

BEHAVIORALGroup 12 (O x E x D x F)

Experimental message: Organization x Effectiveness x Scientific data x Factual

BEHAVIORALGroup 13 (I x S x D x M)

Experimental message: Individual x Safety x Scientific data x Misinformation

BEHAVIORALGroup 14 (O x S x D x M)

Experimental message: Organization x Safety x Scientific data x Misinformation

BEHAVIORALGroup 15 (I x E x D x M)

Experimental message: Individual x Effectiveness x Scientific data x Misinformation

BEHAVIORALGroup 16 (O x E x D x M)

Experimental message: Organization x Effectiveness x Scientific data x Misinformation

Sponsors

The University of Hong Kong
Lead SponsorOTHER
London School of Hygiene and Tropical Medicine
CollaboratorOTHER
Nagasaki University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.

Exclusion criteria

* Caregivers who do not agree to participate in survey, experiment, or both. * Caregivers with daughters who have already received two or more HPV vaccines.

Design outcomes

Primary

MeasureTime frameDescription
Willingness to receive HPV vaccines for daughtersThis experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.

Secondary

MeasureTime frameDescription
Confidence in HPV vaccine safetyThis experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.A degree of a change in confidence regarding HPV vaccine safety after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less confident that the HPV vaccine is safe, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORLeesa Lin, PhD

London School of Hygiene and Tropical Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026